{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:51:12Z","timestamp":1792752672695,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1124\/jpet.122.001413","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T13:37:58Z","timestamp":1683725878000},"page":"205-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic Role of Contraindicated Drugs in Hospitalized Patients with Decompensated Heart Failure"],"prefix":"10.1016","volume":"386","author":[{"given":"Olivia","family":"Parish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cannata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamir","family":"Shamsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jordan-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Albarjas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Piper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bromage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"McDonagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001413_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000086521.95630.5A","article-title":"Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"42","author":"Alderman","year":"2003","journal-title":"Hypertension"},{"key":"10.1124\/jpet.122.001413_bib2","doi-asserted-by":"crossref","first-page":"i4857","DOI":"10.1136\/bmj.i4857","article-title":"Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study","volume":"354","author":"Arf\u00e8","year":"2016","journal-title":"BMJ"},{"key":"10.1124\/jpet.122.001413_bib3","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001413_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001413_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10741-021-10135-4","article-title":"Polypharmacy definition and prevalence in heart failure: a systematic review","volume":"27","author":"Beezer","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1124\/jpet.122.001413_bib6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/ejhf.412","article-title":"Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease","volume":"17","author":"Bello","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/jpet.122.001413_bib7","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1532-5415.2004.52456.x","article-title":"Risk of congestive heart failure in an elderly population treated with peripheral alpha-1 antagonists","volume":"52","author":"Bryson","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1124\/jpet.122.001413_bib8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001413_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.amjcard.2009.03.030","article-title":"Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure","volume":"104","author":"Dhaliwal","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1124\/jpet.122.001413_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archinte.162.3.265","article-title":"Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study","volume":"162","author":"Feenstra","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1124\/jpet.122.001413_bib11","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.106.616219","article-title":"Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction","volume":"113","author":"Gislason","year":"2006","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001413_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archinternmed.2008.525","article-title":"Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure","volume":"169","author":"Gislason","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1124\/jpet.122.001413_bib13","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/jpet.122.001413_bib14","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001413_bib15","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1136\/bmj.330.7504.1370","article-title":"Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study","volume":"330","author":"Hudson","year":"2005","journal-title":"BMJ"},{"key":"10.1124\/jpet.122.001413_bib16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jchf.2018.06.015","article-title":"Safety of Alpha-Adrenergic Receptor Antagonists in Heart Failure","volume":"6","author":"Jackevicius","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1124\/jpet.122.001413_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2016.04.187","article-title":"The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials","volume":"218","author":"Kang","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1124\/jpet.122.001413_bib18","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(04)16299-5","article-title":"Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study","volume":"363","author":"Mamdani","year":"2004","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001413_bib19","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2459\/JCM.0b013e328362c6ae","article-title":"Erythropoietin in cardiac disease: effective or harmful?","volume":"14","author":"Mastromarino","year":"2013","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1124\/jpet.122.001413_bib20","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1093\/eurheartj\/ehab670","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1124\/jpet.122.001413_bib21","first-page":"e32","article-title":"Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association","volume":"134","author":"Pagell","year":"2016","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001413_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12916-015-0285-8","article-title":"Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks","volume":"13","author":"Scarpignato","year":"2015","journal-title":"BMC Med"},{"key":"10.1124\/jpet.122.001413_bib23","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ejheart.2008.07.013","article-title":"Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials","volume":"10","author":"Scott","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/jpet.122.001413_bib24","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001413_bib25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2143\/AC.64.4.2041613","article-title":"Safety and efficacy of doxazosin as an \u201cadd-on\u201d antihypertensive therapy in mild to moderate heart failure patients","volume":"64","author":"Spoladore","year":"2009","journal-title":"Acta Cardiol"},{"key":"10.1124\/jpet.122.001413_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.14740\/cr1078","article-title":"Association of Potentially Inappropriate Medications With All-Cause Mortality in the Elderly Acute Decompensated Heart Failure Patients: Importance of Nonsteroidal Anti-Inflammatory Drug Prescription","volume":"11","author":"Sunaga","year":"2020","journal-title":"Cardiol Res"},{"key":"10.1124\/jpet.122.001413_bib27","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001413_bib28","doi-asserted-by":"crossref","first-page":"l223","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"key":"10.1124\/jpet.122.001413_bib29","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"10.1124\/jpet.122.001413_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977","article-title":"Polypharmacy in Older Adults Hospitalized for Heart Failure","volume":"13","author":"Unlu","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1124\/jpet.122.001413_bib31","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/ejhf.432","article-title":"Erythropoiesis-stimulating agents in heart failure: leave it or re-take it?","volume":"17","author":"Volpe","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/jpet.122.001413_bib32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.amjmed.2010.08.017","article-title":"Trends in comorbidity, disability, and polypharmacy in heart failure","volume":"124","author":"Wong","year":"2011","journal-title":"Am J Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:30:13Z","timestamp":1739971813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524170668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0022356524170668"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001413","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Role of Contraindicated Drugs in Hospitalized Patients with Decompensated Heart Failure","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}